page_accueil_3_actus

Articles

• Poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
  15 May 2024, by Emmanuelle BETTENDORF

  The poster, entitled “VECTrans® technology: a powerful delivery approach to significantly enhance efficacy of therapeutic oligonucleotides in retina cells”, outlines a study assessing Vect-Horus’ proprietorial VECTrans® technology. This is based on the specific design and optimization of molecular vectors that, once joined to a payload, enable its delivery to target specific organs in the body.
  The study showed that these vectors have the potential to improve delivery of medication to the (…)

• Vect-Horus and RadioMedix announce the signing of a LOI to co-develop a Vect-Horus’ radio-theranostic agent for Glioblastoma
  6 March 2019, by Jonathan NOWAK

  Marseille, France- Houston - March 5, 2019 - Vect-Horus and RadioMedix announced today the signing of a Letter of Intent (LOI) to establish an agreement for the co-development of a Vect-Horus theranostic agent for the diagnostic and radiotherapy of Glioblastoma Multiforme (GBM) of the brain.
  This partnership will marry the expertise of Vect-Horus in targeting tumors with its technology VECTrans® and the know-how of RadioMedix in developing and conducting pre-clinical evaluation and (…)

• Vect-Horus enters into Collaboration and License Agreement with ONO Pharmaceutical Co., Ltd.
  26 March 2019, by Jonathan NOWAK

  Vect-Horus S.A.S. announced today the signing of a collaboration and license agreement with Ono Pharmaceutical Co., Ltd., focused on the development of novel molecules targeting neurodegenerative diseases

• Vect-Horus announces agreement with Johnson&Johnson Innovation
  18 January 2019, by Jonathan NOWAK

  Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

• Meet Vect-Horus at BIO Spring Vienna
  18 January 2019, by Jonathan NOWAK

  VECT-HORUS will attend BIO Europe from March 25–26, 2019
  If you are interested to meet, please use the B2B Partnering system.
  https://ebdgroup.knect365.com/bioeu...

• Vect-Horus will be attending the EANM’19 Congress in Barcelona
  3 September 2019, by Elodie DORMES

  Cedric MALICET PhD, Oncology Project Manager and Elodie DORMES, Business Development Manager will attend EANM from 12-16 October, 2019 in Barcelona to discuss Peptide Receptor Radionuclide Therapy strategy and partnered Vect-Horus’ products.

• Meet Vect-Horus at BIO Japan
  3 September 2019, by Elodie DORMES

  Dr Jamal TEMSAMANI, Drug Development and Corporate Director will attend BIO Japan from October 9–11, 2019
  If you are interested to meet, please use the B2B Partnering system.

• AD/PD 2019​ International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders in LISBON
  28 January 2019, by Jonathan NOWAK

  Marion DAVID and Romy COHEN will present the “Development of vectors that cross the blood brain barrier to enhance CNS drug delivery in neurodegenerative diseases” in session A: β-Amyloid Diseases poster n°ADPD9-1832

• Signature of a Research Common Lab with the Institute for NeuroPhysiopathology (UMR7051 CNRS-AMU)
  28 January 2019, by Jonathan NOWAK

  Since its incorporation in 2005 VECT-HORUS is a leading partner of the French academic institutions CNRS and Aix-Marseille University. Indeed, the company as a spin-off of the NICN (UMR7259 CNRS-AMU) now Institute for NeuroPhysiopathology INP (UMR7051 CNRS-AMU) directed by Dr. Michel KHRESTCHATISKY, cofounder of the company, develops inventions and technologies derived from the “BBB and Neuroinflammation Team”. VECT-HORUS has established a long-term highly efficient collaboration with this (…)

• Vect-Horus announces Collaboration and Option Agreement with ASTELLAS Pharma
  4 June 2019, by Jonathan NOWAK

  Vect-Horus announced today the signing of the Research Collaboration and Option Agreement (the “Agreement”) with Astellas Pharma Inc., a Japan based pharmaceutical company (“Astellas”). Vect-Horus will use its proprietary technology VECTrans® to transport Astellas’ antibody to the brain for the treatment of CNS diseases.